Company intelligence / Profile preview

Criceto

Ownership: Private
Development stage: Phase 3

Overview

Criceto IKM B.V. is developing APORON®, an oromucosal apomorphine spray currently in Phase 3 trials as a rescue treatment for OFF episodes in Parkinson’s disease. The product aims to become the first-line rescue therapy and has been licensed ex-US/Canada to Orion Corporation.

Therapeutic areas: Neurology
Modalities: Small moleculeSpray formulation
Industry: Biotech

Drug pipeline

1 asset

Aporon

Partnerships

Orion Corporation – exclusive license agreement for APORON® outside US/Canada

Beyond the preview

Go deeper on Criceto.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Criceto.

Explore the full profile